Information supplied here is not intended to replace advice from your doctor. Our products are not intended to diagnose, treat, prevent or cure any disease.
Cannabidiol (CBD) has been used in the management of several human health conditions and has proven to be an effective therapy against many health issues. Currently, there are few studies that aim at studying the effectiveness of cannabis in allergic conditions such as Asthma.
UK and Israel are in the forefront of studying if Cannabinoid is an effective treatment for Asthma. Asthma is a condition that is related to inflammation on the respiratory system. It is a condition that affects over 5 million people in Britain, and therefore there is a need to conduct studies that can lead to awareness of the potential for therapeutic cannabis treatment for sufferers of Asthma. The Hebrew University of Jerusalem in Israel together with CIITECH a UK based firm it as the forefront of this research.
What Motivates This Study?
Asthma patients have reported improvement when corticosteroids and bronchodilators are used to treat them. However, finding another friendly therapy that can work along these is essential to help fight the increased cases of Asthma that have been reported in the recent past. Therefore based on this, UK and Israel based universities came together to study how effective cannabis can be in this treatment.
This is because the plant has had a long history of being used as therapy. Earlier, there were studies that pointed to cannabinoid having the bronchodilatory effects when it was either administered orally or aerosol treatment in Asthmatic Patients.
It has been well established that the CBD has an anti-inflammatory effect. This points to the fact that CBD could be effectively used in the management of Asthma conditions. The endocannabinoid system plays an active role in the functioning of the lungs, and receptors are found in the lung tissue.
Studies carried out in guinea pigs showed that there were changes in inner pressure when breathing after the guinea pigs were challenged with the cannabis-based aerosol. After the study, it was indicated that there were no substantial abnormalities in the control of breathing in the guinea pigs.
There were also further studies that have shown that the cannabinoid receptor agonist is able to counter allergen-induced functions and the histopathological lung changes in the guinea pig allergic asthma-like reaction. In this study, then it can be concluded that there is potential effectiveness also in human beings. This is because, after the aerosol challenge, there was a significant reduction in the occurring of the respiratory abnormalities.
These studies are a baseline that shows the novel non-psychoactive cannabinoid CBD could effectively be used as adjuncts in treating asthmatic patients.
CLINICAL STUDY RESOURCES:
- The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke
- Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma
- Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs
- Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways
- Bronchodilator effect of delta1-tetrahydrocannabinol
- Evaluation of Serum Cytokines Levels and the Role of CBD Treatment in Animal Model of Asthma